Bristol-Myers Squibb Company (BMY): Today's Featured Drugs Loser

Bristol-Myers Squibb Company (BMY) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day down 2.3%. By the end of trading, Bristol-Myers Squibb Company fell 27 cents (-0.8%) to $32.75 on average volume. Throughout the day, 12.3 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9.6 million shares. The stock ranged in price between $32.75-$33.36 after having opened the day at $33.15 as compared to the previous trading day's close of $33.02. Other company's within the Drugs industry that declined today were: Rosetta Genomics (ROSG), down 20.8%, Savient Pharmaceuticals (SVNT), down 14.4%, K-V Pharmaceutical Company (KV.B), down 13.7%, and Accelr8 Technology Corporation (AXK), down 13.2%.

Bristol-Myers Squibb Company, a biopharmaceutical company, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $55.71 billion and is part of the health care sector. The company has a P/E ratio of 14.8, below the average drugs industry P/E ratio of 14.9 and below the S&P 500 P/E ratio of 17.7. Shares are down 6.4% year to date as of the close of trading on Wednesday. Currently there are 11 analysts that rate Bristol-Myers Squibb Company a buy, one analyst rates it a sell, and nine rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

• You can view the full Bristol-Myers Squibb Ratings Report.

On the positive front, Galena Biopharma (GALE), up 28%, EntreMed (ENMD), up 13.1%, Biodel (BIOD), up 11.4%, and Medgenics (MDGN), up 7.3%, were all gainers within the drugs industry with Questcor Pharmaceuticals (QCOR) being today's featured drugs industry winner.

• Use our drugs section to find industry-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

• Find other investment ideas from our top rated ETFs lists.

 

For more information on Bristol-Myers Squibb Company click any of the following:

• Bristol-Myers Squibb Company Stock Price

• Bristol-Myers Squibb Company Analyst Ratings

• Bristol-Myers Squibb Company Key Stats & Profile

• Bristol-Myers Squibb Company Earnings

• Bristol-Myers Squibb Company Ratio Comparison

• Bristol-Myers Squibb Company Growth Rates

• Bristol-Myers Squibb Company Balance Sheet

• Bristol-Myers Squibb Company Cash Flow

• Bristol-Myers Squibb Company Income Statement